Randall B. Brenner is Chief Development & Regulatory at Paratek Pharmaceuticals, Inc. (PRTK). They have made 7 open-market trades across 1 company since 2019, most recently 2023-09-21.
CIK 0001788249
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| PRTK | 85,500 | $191K |
Shares reported on the most recent Form 4, priced at the 2023-09-21 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PRTK | SELL · 10b5-1 | 2023-08-09 | 2023-08-10 | $2.20 | $121K | -0.5% | +0.9% | N/A |
| PRTK | SELL · 10b5-1 | 2022-12-21 | 2022-12-22 | $1.99 | $9K | +19.8% | +20.9% | -0.8% |
| PRTK | SELL · 10b5-1 | 2022-12-12 | 2022-12-14 | $1.97 | $58K | -11.6% | +26.3% | +2.6% |
| PRTK | SELL · 10b5-1 | 2022-10-28 | 2022-11-01 | $3.47 | $12K | -34.5% | -36.5% | -40.5% |
| PRTK | SELL | 2022-08-09 | 2022-08-10 | $2.66 | $104K | -11.6% | -14.3% | -28.3% |
| PRTK | SELL | 2021-12-13 | 2021-12-15 | $4.30 | $188K | -1.4% | +2.1% | -28.8% |
| PRTK | SELL · 10b5-1 | 2021-08-17 | 2021-08-18 | $5.12 | $45K | +7.6% | -6.8% | -1.6% |
| PRTK | SELL | 2021-06-04 | 2021-06-08 | $9.70 | $194K | -27.5% | -34.6% | -48.0% |
| PRTK | SELL | 2020-12-11 | 2020-12-15 | $6.77 | $160K | -9.5% | -3.2% | +13.8% |
| PRTK | SELL · 10b5-1 | 2020-11-13 | 2020-11-16 | $5.93 | $50K | +0.5% | +8.9% | +32.4% |
| PRTK | SELL | 2020-05-12 | 2020-05-14 | $4.75 | $29K | +3.8% | +7.3% | +1.4% |
| PRTK | SELL | 2019-12-12 | 2019-12-16 | $3.10 | $19K | +35.7% | +15.5% | -16.3% |
| PRTK | SELL · 10b5-1 | 2019-10-08 | 2019-10-08 | $3.82 | $19K | -15.6% | +5.2% | +4.2% |
| PRTK | SELL | 2019-10-03 | 2019-10-07 | $3.98 | $31K | -11.3% | +3.1% | +2.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.